Halozyme Therapeutics, Inc. HALO

Company Overview

Halozyme Therapeutics, Inc. is a U.S.-based biotechnology company focused on developing and commercializing drug delivery technologies and specialty biopharmaceutical products. The company operates primarily in the biotechnology and pharmaceutical sectors, with a business model centered on licensing its proprietary ENHANZE® drug delivery platform to large pharmaceutical partners. ENHANZE® is based on recombinant human hyaluronidase technology designed to enable subcutaneous administration of injectable biologics that are traditionally delivered intravenously. Halozyme also markets internally developed products and receives revenue through royalties, milestone payments, product sales, and licensing agreements.

The company’s primary revenue drivers are royalties and collaboration revenues generated from partnered products utilizing ENHANZE®, including therapies commercialized by major pharmaceutical companies such as Roche, Johnson & Johnson, Bristol Myers Squibb, Pfizer, and argenx. Halozyme’s customer base primarily includes global pharmaceutical manufacturers, healthcare providers, and specialty therapeutic markets in oncology, immunology, hematology, and rare diseases. Founded in 1998 and headquartered in San Diego, California, the company evolved from a specialty enzyme therapeutics developer into a platform-focused biotechnology licensing company with a broad portfolio of strategic pharmaceutical partnerships.